Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density by Mendonça, Máira Lupatelli et al.
  Universidade de São Paulo
 
2013
 
Increased vertebral morphometric fracture in
patients with postsurgical hypoparathyroidism
despite normal bone mineral density
 
 
BMC Endocrine Disorders, London, v.13, 2013
http://www.producao.usp.br/handle/BDPI/34712
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Clínica Médica - FMRP/RCM Artigos e Materiais de Revistas Científicas - FMRP/RCM
RESEARCH ARTICLE Open Access
Increased vertebral morphometric fracture in
patients with postsurgical hypoparathyroidism
despite normal bone mineral density
Maira L Mendonça1, Francisco A Pereira1, Marcello H Nogueira-Barbosa1, Lucas M Monsignore1, Sara R Teixeira1,
Plauto CA Watanabe2, Lea MZ Maciel1 and Francisco JA de Paula1,3*
Abstract
Background: The mechanism behind parathyroid hormone (PTH) activation of bone remodeling is intimately
dependent on the time of exposure of bone cells to hormone levels. Sustained high PTH levels trigger catabolism,
while transitory elevations induce anabolism. The effects of hypoparathyroidism (PhPT) on bone are unknown. The
objective was to study the impact of PhPT on bone mineral density (BMD), on the frequency of subclinical vertebral
fracture and on mandible morphometry.
Methods: The study comprised thirty-three postmenopausal women, 17 controls (CG) and 16 with PhPT (PhPTG)
matched for age, weight and height. Bone mineral density (BMD) of lumbar spine, total hip and 1/3 radius,
radiographic evaluation of vertebral morphometry, panoramic radiography of the mandible, and biochemical
evaluation of mineral metabolism and bone remodeling were evaluated in both groups.
Results: There were no significant differences in lumbar spine or total hip BMD between groups. There was marked
heterogeneity of lumbar spine BMD in PhPTG (high = 4, normal = 9, osteopenia = 1, and osteoporosis = 2 patients).
BMD was decreased in the 1/3 radius in PhPTG P < 0.005). The PhPTG group exhibited an increased frequency of
morphometric vertebral fractures and decreased mandible cortical thickness.
Conclusion: The study suggests that vertebral fragility occurs in PhPT despite normal or even high BMD. The
current results encourage further studies to evaluate the use of panoramic radiography in the identification of
osteometabolic disorders, such as PhPT and the development of a more physiological treatment for PhPT.
Keywords: Postsurgical hypoparathyroidism, Osteoporosis, Morphometric fracture, Parathyroid hormone, Panoramic
radiography
Background
During this decade a remarkable advance has occurred in
the knowledge about the molecular and cellular action of
PTH on bone [1,2], whereas little progress has been made
regarding the physiological role of PTH secretion in bone
mass development and homeostasis [3]. There are few lines
of evidence suggesting that individuals with normal bone
mass have greater PTH release in response to physiological
stimuli (hyperphosphatemic diet or modest hypocalcemia)
than osteoporotic patients [4,5]. In contrast, several studies
have demonstrated increased bone mass in patients with
chronic postsurgical hypoparathyroidism, (PhPT) [6,7].
However, to date no study has addressed fracture suscepti-
bility in patients with PhPT [6,8].
Although the risk of fracture increases significantly with
decreasing BMD, large observational studies have demon-
strated that osteoporotic fractures can occur across a wide
spectrum of BMDs [9,10]. Most likely, these events are
related not only to bone mass quantity but also to bone
quality, a component not captured by DXA measurements
[10,11]. Great efforts are being currently devoted to the de-
termination of clinical conditions associated with a high
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fracture risk despite an apparent protection by normal or
increased BMD. Algorithms that combine BMD with iden-
tifiable independent risk factors to estimate a 10-year abso-
lute fracture risk are now being used to provide a more
holistic evaluation of absolute fracture risk over a 10-year
period [12]. Attempts to further refine the algorithms have
been made by taking into account novel variables such as
type 2 diabetes mellitus, cardiovascular disease, asthma
and use of tricyclic antidepressants in addition to the trad-
itional variables of fracture risk assessment (FRAX) [13]. In
addition, the use of other specific bone sites which are
largely assessed by radiological exams can potentially be
used for the early recognition of osteoporosis [14]. Ap-
proximately 1 in 3 of all radiological examinations is made
by dentists [15]. Dental panoramic radiographs provide
images of the jaws and there is evidence that jaw BMD and
radiomorphometric indices developed for this site can be
potentially used for the preventive diagnosis of osteopor-
otic patients [16,17] and of fracture susceptibility [18]. The
OSTEODENT study suggested that an automatic measure-
ment of mandible cortical bone thickness on panoramic
radiographs is a valid test for the diagnosis of osteoporosis
in women aged 45 to 70 years [18]. Bone mass of the
mandible have never been evaluated in patients with
chronic PhPT.
The present study was designed to evaluate BMD (lum-
bar spine, total hip, femoral neck, 1/3 radius and total
body), vertebral subclinical fracture and cortical thickness
in the inferior region of the mandible in a homogenous
group of patients with chronic PhPT. All patients were
women previously submitted to thyroidectomy due to
atoxic benign multinodular goiter. Additionally, we assessed
serum levels of insulin-like growth factor (IGF-I), receptor
activator of nuclear factor-κB ligand (RANK-L), osteoprote-
gerin (OPG), 25-hydroxyvitamin D (25-OH-D), and bone
remodeling markers [serum osteocalcina (OC) and urinary
deoxypyridinoline (DPD)].
Subjects and methods
Subjects
The study was conducted on 33 postmenopausal women
whose clinical characteristics are shown in Table 1. The
study group included 16 patients with PhPT (PhPTG) fol-
lowed up at the Outpatient Clinic of Osteometabolic
Disorders of the University Medical Center, School of
Medicine of Ribeirão Preto, University of São Paulo
(FMRP-USP). The diagnosis of permanent PhPT was estab-
lished by the concomitant presence of low circulatory levels
of calcium and PTH after thyroidectomy, as well as by the
requirement of continued calcium and vitamin D treatment
to maintain serum calcium levels within the normal range.
The control group (CG) consisted of 17 adult women,
matched to the PhPTG for age, weight, height and body
mass index (BMI) (Table 1). The general exclusion
criteria established for both groups were a personal or
family history of osteometabolic disorders, alcohol abuse,
smoking, hepatic or renal disease, or using medications
known to interfere with mineral metabolism (anabolic
steroids, glucocorticoids, anticonvulsants, diuretics or
medication for the treatment of osteoporosis). Addition-
ally, no woman, in both group had premature ovarian
failure. The study was approved by the Ethics Committee
of the School of Medicine of Ribeirão Preto, University of
Table 1 Clinical characteristics and biochemical evaluation of control subjects (CG) and of patients with postsurgical
hypoparathyroidism (PhPTG)
CG (n = 17) PhPTG (n = 16) Estimated difference p-value
[C.I.(95%)]
Age (year) 58.0 ± 6.1 62.3 ± 8.9 −4.31(−9.69;1.06) P = 0.2
Weight(kg) 71.8 ± 13.7 72.6 ± 10.9 −0,82(−9.63;7.98) P = 0.9
Height (m) 1.58 ± 6.4 1.54 ± 7.9 4.18(−0.95;9.31) P = 0.8
BMI (kg/m2) 28.5 ± 5.5 30.3 ± 4.2 −1.84(−5.33;1.65) P = 0.4
Duration of PhPT - 15.3 ± 12.4
Total calcium (mmol/L) 2.43 ± 0.13* 2.05 ± 0.21 1.45(0.95;1.96) P <0.0001
Ca X Pi 3.11 ± 0.63 3.21 ± 0.59 −1.15(−6.51;4.21) P = 0.50
Albumin (g/L) 44.1 ± 2.4* 42.3 ± 1.8 0.18(0.02;0.33) P < 0.05
Phosphorus (mmol/L) 1.29 ± 0.22* 1.57 ± 0.32 −0.86(−1.46;-0.27) P < 0.05
Alkaline phosphatase (U/L) 235.4 ± 65.8 198.1 ± 37.14 37.29(−1;75.58) P = 0.09
Creatinine (μmol/L) 57.96 ± 7.63* 69.39 ± 21.35 −0.30(−0.15;-0.005) P < 0.05
PTH (ng/L) 42.0 ± 18.7* 5.9 ± 4.6 36.05(26.23;45.88) P < 0.0001
25-hydroxyvitamin D (nmol/L) 82.0 ± 35.02 100.8 ± 31.47 −18.9(−42.6;4.85) P = 0.11
IGF-I (μg/L) 68.76 ± 43.55 51.94 ± 19.15 16.83(−7.33;40.98) P = 0.53
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São Paulo (9523/2008). All subjects gave written informed
consent.
The PhPT group had been on treatment for 15.3 ±
12.4 years, with daily intake of elemental calcium, calcitriol
and L-thyroxin of 1713 ± 419 mg, 0.33 ± 0.18 μg and 99.3
± 42.1 μg, respectively. The treatment target was to main-
tain serum total calcium in the lower limit of normal refer-
ence values and to keep serum levels of phosphorus and
TSH in the normal range. We excluded from this group all
individuals with a history of hyperthyroidism and those
with a diagnosis of thyroid cancer, as well as individuals
with a diagnosis of pseudohypoparathyroidism and auto-
immune hypoparathyroidism.
Methods
Blood and urine collections and radiographic documen-
tation were performed on two days. On the first day,
blood and second void urine were samples collected in
the morning between 7:00 and 9:00 after a 10–12 hour
fast and kept in an ice-chilled container until centrifuga-
tion. Serum aliquots were stored at −70°C until assess-
ment, with all determinations being carried out in the
same assay. Subsequently, the volunteers were taken to
the Image Center of the University Hospital, FMRP-USP,
for DXA (dual energy X-ray absorptiometry) scan in
total body, lumbar spine, proximal femur and forearm
and standard thoracic and lumbar spine X-rays. On the
second day, the individuals went to the Radiology
Service of the Dental School of Ribeirão Preto, USP, to
perform digital panoramic radiography.
Serum levels of calcium, phosphorus, alkaline phosphat-
ase and creatinine were determined with an automatic bio-
chemical analyzer (KoneLab 6.0, Winer, Argentina) on the
day of blood collection. Serum IGF-I was measured by en-
zyme immunoassay [intra-assay coefficient of variation
(CV) = 9.5%; Immunodiagnostic Systems, Fountain Hills,
AZ]. Also, serum OC (CV = 5.6%; Quidel, San Diego, CA,
USA), 25-OH-D (CV= 7.2%; Immunodiagnostic System,
Fountain Hills, AZ), OPG (CV= 5.6%; Quidel, San Diego,
CA, USA) and RANKL (CV = 6.8%; Biomedica, Austria)
and urinary DPD (CV= 6.7%; Quidel, San Diego, CA,
USA), were measured by enzyme immunoassay. Serum
PTH was measured by chemiluminescence (CV = 4.7%;
SIEMENS, Los Angeles, CA, USA).
Bone mineral density
BMD was measured by DXA at the femoral neck, total hip,
lumbar spine (L1-L4) and distal radius by a trained radio-
logic technician (Hologic 4500 W densitometer, Hologic
Inc., Bedford, MA, USA). In vivo precision was 1.2% for
L1-L4, 2.3% for femoral neck, 2.7% for total hip and 1.7%
for 1/3 radius, respectively. BMD values were expressed as
g/cm2 and T-Score.
Vertebral morphometry
Lateral thoracic and lumbar spine radiographs were taken
for each patient and images were digitized using a Vidar
DiagnosticPro scanner with a spatial resolution of 84 m
and the gray scale represented by 8 bits/pixel. Six points
were marked with electronic calipers on each of the 13 ver-
tebral bodies from T4 to L4 using K-PACS Workstation
software, v 1.6.0. These points were positioned on the
outer edge of the upper and lower endplates. Using the six
points, the anterior, middle and posterior heights were
determined for each vertebral body in millimeters. Image
analysis was carried out by consensus between 2 radiolo-
gists, both performed by blind assessment. A senior mus-
culoskeletal radiologist reviewed all images in which any of
the measured vertebral height ratios in a single film was
<0.75 and also solved difficult cases when any doubt was
present regarding the positioning of the calipers or to
check if the encountered deformity was related to patholo-
gies other than insufficiency fractures. The last analysis
was also performed by blind assessment.
The criteria of vertebral deformity were: 1) more than
a 20% reduction between two of the above measures
and/or a 20% reduction in the relation between any one
of the above measurements and the measurement of the
corresponding region of the vertebral body immediately
superior or inferior to each vertebral body analyzed, or
2) a reduction ≥ 4 mm in the absolute vertebral height
value in relation to the other heights in the same verte-
bral body and in relation to the similar height in the im-
mediate neighboring vertebral bodies.
Panoramic radiograph
All panoramic radiographs were obtained with an RX Ver-
aviewepocs Digital Panoramic instrument (J. Morita Co).
Digital images were examined with RADIOIMP software
(Radiomemory, Brazil). In this panoramic images, the
thickness of the inferior cortical region of the mandible
bone were measured on both sides and in two regions
(mental and goniac). The digital panoramic radiograph
was inserted into the software and calibrated using magni-
fication (30%) and resolution (300 d.p.i.) factors [19]. The
projected areas of interest are used for the determination
of the Mental Index and Goniac Index, as previously
described [20,21].
Statistical analysis
All statistical analyses were performed using SAS 9.0 soft-
ware (SAS/STATW User’s guide version 9.0, Cary, NC,
USA: SAS Institute Inc., 2002). The Student t–test was ap-
plied using the PROC T TEST of the SAS 9.0 software to
compare the results of the two groups. To determine the
association of the variables of interest (BMD with hypo-
parathyroidism duration, IGF-I and 25-OH-D, simple
linear regression models were adjusted, yielding the
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regression coefficients and R-square, through the REG
procedure of the SAS 9.0 software. Considering the
method described by Hsieh et al. [22] for determining the
sample size required for the estimation of a correlation co-
efficient and for linear regression models, a sample of size
16 is sufficient for estimating a correlation coefficient
equal to 0.65 with a level of significance of 0.05 and a
power of 0.20. Thus, it was established that the sample
size in each group should be at least 16. Data are
expressed as mean ± SD.
Results
Table 1 shows that both groups were appropriately matched
for age (range: CG= 49–70 vs PhPTG= 45–77 years),
weight (range: CG= 46-94.6 vs PhPTG= 54.8–98.5 Kg)
height (range: CG= 1.47–1.74 vs PhPTG= 1.47–1.69 m),
BMI (range: CG= 16.9–36.1 vs PhPTG= 23.3–38.0 kg/m2).
The duration of postsurgical hypoparathyroidism ranged
from 2 to 44 years (mean = 15.3 ± 12.4 years). Both groups
presented normal serum creatinine levels (CG= 57.96 ±
7.63 μmol/L vs PhPTG= 69.39 ± 21.35 μmol/L). All volun-
teers had creatinine clearance above 60 ml/min. The serum
levels of TSH were normal in PhPT group (PhPTG= 2.6 ±
1.0 mIU/L).
Serum levels of total calcium (CG = 2.43 ± 0.13 vs
PhPTG= 2.05 ± 0.21 mmol/L; P < 0.0001), total calcium
corrected by albumin (CG = 2.39 ± 0.21 vs PhPTG= 2.01
± 0.26 mmol/L, P < 0.005), as well as PTH (CG= 4.45 ±
1.99 vs PhPTG= 0.63 ± 0.49 pmol/L, P < 0.0001) were
significantly lower in PhPTG. The control group showed
significantly lower serum phosphorus levels than PhPTG
(CG= 1.29 ± 0.22 vs PhPTG= 1.57 ± 0.32 mmol/L, P <
0.01). The groups showed nonsignificant differences in
circulatory levels of 25-OH-D and IGF-I (Table 1).
Circulatory levels of the biochemical marker of bone for-
mation, OC, were significantly lower in PhPTG (6.75 ±
2.36 μg/L) than in CG (9.64 ± 2.54 μg/L), P < 0.01, whereas
there was no significant difference in urinary excretion of
DPD (CG= 7.44 ± 3.0 vs PhTHG= 11.15 ± 13.16 nmol/
mmol creatinine; p = 0.77). Both groups presented similar
serum levels of RANKL (CG= 0.26 ± 0.21 vs PhPTG= 0.29
± 0.27 pg/dl; p = 0.57) and OPG (CG= 0.094 ± 0.012 vs
PhPTG= 0.1 ± 0.025 pmol/L; p = 0.44).
Total body BMD was slightly higher in PhPTG (0.923
± 0.13 g/cm2) than in CG (0.904 ± 0.10 g/cm2). The
mean values of lumbar spine BMD did not differ signifi-
cantly between groups (CG = 0.970 ± 0.15 g/cm2 vs
PhPTG = 1.093 ± 0.26 g/cm2). However, there was wide
heterogeneity of T-score distribution within PhPTG, with 4
patients presenting a high T-score (> + 2.0 SD), 9 patients
presenting a normal T-score (between +2 and −1.0 SD), 1
patient presenting a T-score compatible with osteopenia,
and 2 patients presenting L1-L4 BMD compatible with
osteoporosis (T-score < −2.5 SD) (Figure 1). Lumbar spine
BMD was also evaluated after exclusion of the dominant
vertebral body when there was a difference higher than 1
SD between two contiguous vertebral bodies. The results
obtained in this second evaluation did not differ significantly
from those obtained in the first evaluation (CG= 0.970 ±
0.153 vs PhPTG= 1.088 ± 0.250 g/cm2). Both groups
showed similar BMD values in femoral neck (CG= 0.826 ±
0.111 vs PhPPG= 0.865 ± 0.159 g/cm2) and total hip (CG=
0.961 ± 0.145 vs PhPTG= 0.953 ± 0.162 g/cm2) (Figure 1).
However, BMD values for the 1/3 radius were significantly
lower in PhPTG compared to control group (CG= 0.630 ±
0.07 vs PhPTG= 0.570 ± 0.09, P < 0.05) (Figure 1).
Table 2 shows that 10 of the 16 PhPTG patients (63%)
had morphometric vertebral fractures, as opposed to only
2 CG individuals. The table also shows that morphometric
vertebral fractures were not restricted to individuals with a
low bone mass. Actually, 3 of the 4 patients with a BMD
T-score above + 2SD had subclinical fractures in the thor-
acic and/or lumbar spine.
There was a significant correlation between the duration
of postsurgical hypoparathyroidism and lumbar spine
BMD (Figure 2). However, there was no correlation be-
tween the duration of postsurgical hypoparathyroidism
and vertebral fracture. There was no correlation between
BMD and serum IGF-I levels or between BMD and serum
25-OH-D levels.
There was no significant difference between groups
regarding inferior cortical thickness in the region of the
mandible angle (goniac). Inferior cortical thickness in the
mental mandible was significantly decreased in PhPTG
(Table 2). There was no significant correlation between
lumbar spine BMD and cortical thickness in the mental re-
gion of the mandible. However, this last index was signifi-
cantly and positively correlated with 1/3 distal forearm
BMD (Figure 2).
Discussion
Skeletal fracture has not been considered a potential prob-
lem in postsurgical hypoparathyroidism, especially after
clinical investigation, based on surrogate parameters, have
shown that BMD is preserved or even enhanced in PhPT
[7,23]. The present study demonstrated that patients with
PhPT have marked heterogeneity in lumbar spine BMD,
usually exhibiting high or normal bone mass, while densi-
tometric osteoporosis is uncommon. Paradoxically, we
have observed a high frequency of morphometric fracture
of lumbar and thoracic vertebrae in patients with PhPT,
which is not restricted to those with low bone mass. A
previous nonvertebral fracture was present in one patient
of the PhPT group, while no individual of the control
group sustained clinical fracture. In addition, our results
show that panoramic radiography of the mandible is a use-
ful tool for the recognition of bone disorders in PhPT.
These results are of great significance in the clinical
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setting since these data correspond to the first evidence of
increased risk of fractures in postsurgical hypoparathyr-
oidism. Therefore, these preliminary results encourage
further investigation of the etiopathogenesis and preva-
lence of this condition and a more appropriate approach
to the management of this particular group of patients.
There are studies showing a differential impact of PhPT
on diverse bone sites, the increase in BMD being higher in
the lumbar spine than in the proximal femur [23], whereas
forearm BMD was not positively affected [24]. For
Instance, Duan et al. evaluated 10 postmenopausal women
harboring postsurgical hypoparathyroidism. The duration
Figure 1 Distribution of bone mineral density values of lumbar spine (A), femoral neck (B), total hip (C) and 1/3 d forearm (D) of the
control group (CG) and of the postsurgical hypoparathyroidism group (PhPTG).
Table 2 Number of vertebral fractures, bone mineral density (T-score) and mental index in the control group (CG) and
postsurgical hypoparathyroidism group (PhPTG)
CG Vertebral fracture T-score (L1-L4) MI * PhTPG Vertebral fracture T-score (L1-L4) MI
1 0 −2 3.02 1 0 2.7 3.36
2 0 1.2 3.59 2 0 0.3 2.80
3 0 0.0 3.60 3 0 −0.8 1.82
4 0 −1.8 3.32 4 3 (T6, T7, T11) 0.2 3.35
5 4 (T5, T6, T7, T11) 1.8 3.9 5 6 (T6, T8, T9, T10, T11, T12) 3.1 3.09
6 0 −1.6 3.48 6 3 (T6, T8, T11) −3.4 2.32
7 2 (T5, T6) −0.6 3.37 7 0 −0.9 2.20
8 0 −3.6 1.66 8 3 (L1, L3, L4) −0.5 3.50
9 0 −0.2 4.44 9 1 (T5) 1.2 3.30
10 0 −1 4.04 10 0 −1.5 2.26
11 0 −2.4 3.25 11 8 (T7, T8, T10, T11, L1, L2, L3, L4) 3.4 4.22
12 0 −0.2 2.74 12 1 (T11) 4.9 3.35
13 0 0.5 3.54 13 1 (L4) −1 2.02
14 0 1.1 3.30 14 0 0.1 3.44
15 0 −0.8 4.21 15 2 (T7, T8) −2.9 2.05
16 0 1.4 2.81 16 1 (T11) 0.9 1.38
17 0 −0.2 4.39 - - - -
Mean ± SD - −0.49 ± 1.47 3.45 ± 0.68 - - 0.36 ± 2.28 2.79 ± 0.78
*Indicates a significant difference between groups, P < 0.05.
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of PhPT in this group varied from 0.5 to 51 yr. These
authors observed that BMD in patients with hypopara-
thyroidism was higher when compared with the age pre-
dicted mean at the lumbar spine and proximal femur, but
not at the distal radius [25]. The present study replicates
this spectrum on a different level, with BMD being only
slightly increased in the lumbar spine due to wide hetero-
geneity among patients and being modestly decreased in
the proximal femur of PhPT patients, whereas bone mass
was decreased in the distal forearm. The divergences be-
tween studies are probably due to differences in the profile
of the patients examined. Different from other studies, we
adopted more rigid criteria for the selection of volunteers.
Patients with previous diagnosis of thyroid cancer and
hyperthyroidism were excluded, ultimately avoiding the
inclusion of individuals affected by other disorders asso-
ciated with bone loss and fracture. Another difference is
that previous studies included pre- and postmenopausal
women, whereas only postmenopausal women partici-
pated in the present study. Akin to other studies, our
patients showed a great variability in the duration of PhPT
[25]. This aspect can, at least in part, account for the large
variation of BMD values in patients with PhPT. The rele-
vance of this point is reinforced by the strong positive cor-
relation between PhPT duration and BMD.
It should be mentioned that BMD assessment by DXA
in PhPT was comparable to that described in primary
hyperparathyroidism. It is well known that cortical bone is
preferentially affected by primary hyperparathyroidism,
and the same pattern was observed in PhPT. It should be
pointed out that the control group also had distal forearm
BMD within the osteopenia range, a fact possibly related
to population characteristics, since the same profile was
observed in normal individuals in previous studies per-
formed in our laboratory [25]. However, PhPT patients
showed significantly lower distal forearm BMD compared
to control individuals. Furthermore, the panoramic radiog-
raphy of the mandible was especially useful to capture the
reduction in cortical thickness in another bone site.
Despite the BMD of the lumbar spine, 63% of patients
with PhPT showed at least one morphometric fracture in
the dorsal/lumbar spine, and morphometric fractures were
also detected in patients showing high bone mass. No
study has previously evaluated fracture susceptibility in
PhPT. The results indicate deterioration of bone quality,
the other component that assures bone strength. A previ-
ous study [6] detected by Fourier transform infrared im-
aging of transiliac biopsies that the collagen cross-link
ratio was significantly higher in hypoparathyroid subjects
compared to normal individuals. Based on these and other
results the authors suggested that bone has low turnover
rate and acquires a mature or hypermature profile in
PhPTH [6]. Although, we have assessed only osteocalcin
and DPD as biochemical bone markers of bone remodel-
ing, our results support previous data obtained by bone
histomorphometry. Decreased osteocalcin reflects reduced
osteoblast activity in hypoparathyroidism. A reduced rate
of bone remodeling which was reversed by intermittent ad-
ministration of subcutaneous PTH has also been demon-
strated by histomorphometric analysis in PhPT patients
[7]. In support of these data we observed that osteocalcin
levels were significantly lower in PhPT patients than in
Figure 2 (Right) Correlation between bone mineral density in lumbar spine and duration of postsurgical hypoparathyroidism (p = 0.03
adjusted by TSH; R2 = 0.35) and (Left) correlation between bone mineral density and cortical thickness of the mental region of the
mandible (p < 0.01; R2 = 0.30).
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normal individuals. On a long-term basis, the impairment
of bone renewal is implicated in inefficient repair of micro-
damage and ultimately in fracture susceptibility.
Other factors must be taken into account regarding im-
pairment of bone strength in PhPT patients, especially in
those with high BMD. Thickening of trabecular bone
could compromise bone strength by reducing resilience
[26,27]. In normal bone, the elastic properties of trabecu-
lar bone allow the skeleton to absorb energy by deforming
reversibly when loaded [28]. Although the greater mineral
content in the hypoparathyroid bone might produce
greater material stiffness, it may do so at the expense of
the ability of the bone to deform and thus to absorb and
dissipate energy. Without elastic deformation, it is possible
that hypoparathyroid bone could be vulnerable to struc-
tural failure. Because the effectiveness of bone in stopping
cracks is directly proportional to the stiffness ratio across
its internal interfaces, a homogeneous material will be less
effective in slowing or stopping cracks initiated in the
bone matrix, permitting cracks to grow more quickly to
critical size and ultimately increase fracture risk [29,30].
Previous studies have shown that growth hormone defi-
ciency impairs PTH circadian rhythm [31] and PTH ac-
tion [32,33]. In order to detect hormonal alterations in the
growth hormone (GH)/IGF-I axis, in the present study we
assessed serum IGF-I levels and the results showed that
PhPT patients have a lightly lower circulatory IGF-I level
than control individuals. However, we did not measure
GH secretion or GH/IGF-I sensitivity in PhPT patients.
Additionally, vitamin D sufficiency was evaluated and all
patients showed normal serum 25(OH)D levels conferring
a convenient substrate supply for paracrine/autocrine syn-
thesis of 1,25(OH)2D. Endocrine levels of 1,25(OH)2D are
largely dependent of PTH secretion, but all patients were
taking physiological doses of calcitriol. Although, no
woman of the control group was receiving calcium and
vitamin D supplementation, they exhibited normal serum
levels of 25-OHD. In agreement with these results, we did
not observe a high frequency of hypovitaminosis D in this
region of the state of São Paulo, Brazil, in previous studies
[34,35]. As vitamin D deficiency is associated with worse
bone outcome, it is likely that our groups were in advanta-
geous conditions compared to other populations with a
higher incidence of vitamin D deficiency [36].
Previous studies have shown increased serum levels of
RANKL and maintained OPG levels in primary hyper-
parathyroidism [37]. Also, it was observed that intermit-
tent administration of PTH to glucocorticoid-treated
patients increases serum levels of RANKL and decreases
serum levels of OPG [38]. In the present study no differ-
ence was detected in RANKL and OPG serum level of
PhPT patients in comparison to control subjects. To our
knowledge, no previous study addressed serum RANKL
levels in postsurgical hypoparathyroidism. Although low
PTH levels might be expected to provoke decreased
RANKL levels, it should be considered that 1,25(OH)2D
stimulates RANKL synthesis.
The present study has some limitation; the number of
patients studied was insufficient to definitively associate
postsurgical hypoparathyroidism with increased fracture
risk. However, these are important preliminary data for a
more comprehensive study to examine the dissociation
between bone fragility and bone mineral density in
patients harboring postsurgical hypoparathyroidism.
Conclusions
Our results suggest that PhPT has a great impact on
bone structure which is not necessarily detected by
BMD density. Subclinical vertebral fracture was identi-
fied in more than 60% of PhPT patients, including those
exhibiting high BMD. Panoramic radiography of the
mandible should be thoroughly scrutinized to determine
its place in the diagnosis or screening of osteoporosis.
This site was useful to reveal cortical changes in PhPT.
Panoramic radiography has the additional advantage of
relying on a dentist for the screening of osteoporotic
patients. The study encourages further investigation to
determine the role of PTH as hormone replacement
therapy in postsurgical hypoparathyroidism.
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